Douglas G. Gray

Douglas Gray is Chair of Locke Lord's Life Sciences Practice Group, focusing on medical device, pharmaceutical and health care-related companies and products. He brings to his clients a broad range of experience in the practice of corporate law, concentrating in the areas of mergers and acquisitions, corporate governance, strategic alliances and commercial ventures. In addition, he enjoys an active collaborations practice, centered on negotiating licensing, joint venture and development agreements relating to intellectual property rights. Douglas is a member of the Firm's Board of Directors and Co-Chairs the Firm's Pro Bono Committee.

Douglas' work in acquisitions, dispositions, joint ventures and other transactions involves representation of individual investors, management teams, corporate buyers and sellers, venture capitalists and private equity firms. This varied representation provides him with a unique understanding of the likely concerns of each party in a sophisticated transaction so that he is well-suited to assist clients in planning and implementing their strategies as well as crafting creative, but cost-effective, solutions to their concerns.

Douglas' experience includes the representation of:

• Imugene Ltd. (IMU:AUX), a clinical stage immuno-oncology company developing a range of new and novel immunotherapies seeking to activate the immune system of cancer patients to treat and eradicate tumors, in its strategic transaction with Precision BioSciences, Inc., valued up to $227 million
• Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) in the sale of its migraine business, including NURTEC® ODT, an innovative dual-acting migraine therapy approved for both acute treatment and episodic prevention of migraine in adults, and zavegepant, to Pfizer in a total deal consideration valued at approximately $13 billion
• Oscor, Inc., a leading designer, developer and manufacturer of highly specialized implantable cardiac pacing leads, venous access systems and diagnostic catheters, in its sale of $220 million to Integer Holdings Corporation
• Shanghai Haohai Biological Technology Co., Ltd., a public company traded on the Hong Kong and Shanghai stock exchanges, in connection with its $40 million Series A preferred equity investment in Eirion Therapeutics, Inc., a biotech startup based in Massachusetts, and related licensing arrangements
• Biohaven Pharmaceutical Holding Company (NYSE: BHVN) in its acquisition of the remaining 58% interest of Kleo Pharmaceuticals, Inc., that it did not previously own and the execution of an exclusive license agreement with Yale University for a novel extracellular degrader technology licensed from the Spiegel Lab
• Biohaven Pharmaceutical Holding Company (NYSE: BHVN) and its affiliate BioShin Limited in a $60 million Series A Preferred equity financing of BioShin Limited, Biohaven's subsidiary
• Leonard Valve Company, a Rhode Island-based designer and manufacturer of water temperature control valves and monitoring devices used in institutional and commercial applications, and its owners in the sale of the equity interests of Leonard Valve to Bessemer Investors
• ActiveCare Inc., and its wholly-owned subsidiary, 4G Biometrics, LLC, in the sale of substantially all of its assets under Sections 105, 363 and 365 of the United States Bankruptcy Code, to Telcare Medical Supply, LLC, a subsidiary of Biotelemetry, Inc. (NASDAQ: BEAT), a leading developer of mobile and wireless medical monitoring devices, for up to an amount exceeding $10 million of total consideration
• Juvenescence Limited, a leading drug development company focused on the development of therapies to increase human longevity
  • In its purchase of 14.4 million shares of AgeX Therapeutics, Inc., for $43.2 million, from its affiliate, BioTime, Inc. (NYSE American: BTX). AgeX is focused on developing novel therapeutics for age-related degenerative disease
  • In a $10 million equity financing of FoxBio Inc. Juvenescence's partner in the joint venture, Antoxerene Inc. (a portfolio company of Ichor Therapeutics, Inc.), is a small molecule developer focused on targeting aging cells
  • In a $6.5 million equity financing of BYOMass Inc., a Massachusetts-based company focused on developing treatments for obesity and cachexia
• Outside general counsel to a number of businesses and insurance companies ranging in size, from a billion dollar annual revenue NYSE manufacturer to privately held companies, in matters varying from acquisitions and dispositions to joint ventures and collaborations
• A publicly traded client in negotiating and drafting a complex strategic alliance with another publicly traded company to jointly produce products by using each company's underutilized assets
• Management teams on general corporate matters, including issues related to contracting, licensing, corporate governance and risk management
• Management teams and boards of directors with strategic planning, acquisitions, dispositions, joint ventures and litigation management